MA27700A1 - Vaccin contre l'hepatite c - Google Patents

Vaccin contre l'hepatite c

Info

Publication number
MA27700A1
MA27700A1 MA28285A MA28285A MA27700A1 MA 27700 A1 MA27700 A1 MA 27700A1 MA 28285 A MA28285 A MA 28285A MA 28285 A MA28285 A MA 28285A MA 27700 A1 MA27700 A1 MA 27700A1
Authority
MA
Morocco
Prior art keywords
hcv
expression
protein
polynucleotide sequence
core protein
Prior art date
Application number
MA28285A
Other languages
English (en)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27700A1 publication Critical patent/MA27700A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à des procédés et à des compositions servant à traiter et à prévenir l'infection par le virus de l'hépatite C (VHC), ainsi que les symptômes et les maladies qui lui sont associés. L'invention concerne en particulier des vaccins à ADN qui codent la protéine du noyau du VHC, et une séquence polynucléotidique qui code au moins une autre protéine du VHC. Lesdits vaccins provoquent l'expression des protéines contenues dans la même cellule, et la séquence de la séquence polynucléotidique codant la protéine du noyau a fait l'objet d'une mutation, ou a été positionnée par rapport à la séquence polynucléotidique codant la ou les autres protéines du VHC, de façon que soit réduit l'effet négatif de l'expression de la protéine du noyau sur l'expression de la ou les autres protéines du VHC.
MA28285A 2002-11-15 2005-05-16 Vaccin contre l'hepatite c MA27700A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
MA27700A1 true MA27700A1 (fr) 2006-01-02

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc
MA28285A MA27700A1 (fr) 2002-11-15 2005-05-16 Vaccin contre l'hepatite c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA28284A MA27699A1 (fr) 2002-11-15 2005-05-16 Vaccin contre vhc

Country Status (21)

Country Link
US (4) US20060246090A1 (fr)
EP (2) EP1560845A1 (fr)
JP (2) JP2006518331A (fr)
KR (2) KR20050085009A (fr)
CN (2) CN1738834A (fr)
AR (1) AR041964A1 (fr)
AU (2) AU2003288084A1 (fr)
BR (2) BR0316244A (fr)
CA (2) CA2504654A1 (fr)
CO (1) CO5700833A2 (fr)
GB (1) GB0226722D0 (fr)
IS (2) IS7830A (fr)
MA (2) MA27699A1 (fr)
MX (2) MXPA05005203A (fr)
NO (2) NO20052149L (fr)
NZ (2) NZ539999A (fr)
PL (2) PL376967A1 (fr)
RU (2) RU2363492C2 (fr)
TW (1) TW200502246A (fr)
WO (2) WO2004046175A1 (fr)
ZA (2) ZA200503802B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (fr) * 2004-10-18 2014-01-08 Globeimmune, Inc. Moyens thérapeutiques à base de levure contre l'infection par hépatite C chronique
ES2551113T3 (es) * 2006-01-04 2015-11-16 Glaxosmithkline Biologicals S.A. Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC
US8211444B2 (en) * 2006-03-09 2012-07-03 Transgene S.A. Hepatitis C virus non structural fusion protein
AU2007345682B2 (en) * 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
JP5683811B2 (ja) * 2006-07-27 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラインフルエンザウイルス様粒子
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
WO2009022236A2 (fr) 2007-08-16 2009-02-19 Tripep Ab Plate-forme immunogène
RU2370776C2 (ru) * 2007-11-08 2009-10-20 Общество с ограниченной ответственностью "Диагностические Центры "Алкор Био" Набор антигенов для раздельного выявления антител к структурным и неструктурным белкам вируса гепатита с
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (fr) * 2008-04-22 2009-10-29 Rutgers, The State University Compositions de produit de construction e2 de vhc et procedes correspondants
WO2010011870A2 (fr) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions et procédés de traitement de l'hépatite c
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
EP2496609A4 (fr) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
CN119504957B (zh) * 2025-01-16 2025-04-25 中山大学 一种佐剂及其在制备疫苗中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
CA2070952A1 (fr) * 1991-06-11 1992-12-12 Makoto Seki Gene du virus de l'hepatite c ou fragment dudit gene, polypeptide code par le gene
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
DE69533167D1 (de) * 1994-10-05 2004-07-22 Apollon Inc Impfstoffe gegen den hepatitis b und c virus
IL118364A0 (en) * 1995-05-22 1996-09-12 Bionova Corp A hepatitis C virus-derived composition methods for the preparation thereof and assays for the detection of hepatitis C virus
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
EP1200465A1 (fr) * 1999-07-09 2002-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services Epitopes antigeniques et polypeptides de mosaique des proteines du virus de l'hepatite c
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2005113691A (ru) 2006-01-27
NO20052149D0 (no) 2005-05-02
NO20052149L (no) 2005-07-11
BR0316244A (pt) 2005-10-04
US20090232847A1 (en) 2009-09-17
CN1738833A (zh) 2006-02-22
MXPA05005202A (es) 2006-01-27
ZA200503802B (en) 2006-08-30
AU2003288072A1 (en) 2004-06-15
AR041964A1 (es) 2005-06-01
EP1560844A1 (fr) 2005-08-10
WO2004046176A1 (fr) 2004-06-03
US20060246090A1 (en) 2006-11-02
TW200502246A (en) 2005-01-16
US20090104231A1 (en) 2009-04-23
IS7831A (is) 2005-04-28
GB0226722D0 (en) 2002-12-24
CN1738834A (zh) 2006-02-22
KR20050085009A (ko) 2005-08-29
PL376882A1 (pl) 2006-01-09
RU2363492C2 (ru) 2009-08-10
AU2003288084A1 (en) 2004-06-15
MXPA05005203A (es) 2006-01-27
NZ539999A (en) 2008-03-28
US20060135451A1 (en) 2006-06-22
NO20052136D0 (no) 2005-05-02
WO2004046175A1 (fr) 2004-06-03
KR20050085010A (ko) 2005-08-29
RU2005113692A (ru) 2006-01-27
CA2504654A1 (fr) 2004-06-03
BR0316291A (pt) 2005-10-11
EP1560845A1 (fr) 2005-08-10
MA27699A1 (fr) 2006-01-02
RU2323744C2 (ru) 2008-05-10
NZ539998A (en) 2008-04-30
JP2006524181A (ja) 2006-10-26
NO20052136L (no) 2005-07-11
PL376967A1 (pl) 2006-01-23
IS7830A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
ZA200503803B (en) 2006-08-30
JP2006518331A (ja) 2006-08-10
CA2504715A1 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
MXPA05005202A (es) Vacuna.
CY1113650T1 (el) Συντηρημενα αντιγονα neisseria
EP1381345A4 (fr) Administration de traitement contre une maladie en aquaculture et en agriculture au moyen de microbes contenant des proteines bio-actives
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
RU2005118419A (ru) Вакцина против вируса лихорадки западного нила
JP2004236637A5 (fr)
ATE495247T1 (de) Chromoprotein und fluoroproteine
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
DE60231057D1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
TW200509964A (en) VP1 of foot-and-mouth disease virus
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
IL75553A0 (en) Ache like peptide
MA27474A1 (fr) Vaccin
Tokutake Complete separation of the triplet components of neurofilament by DE-52 column chromatography depends upon urea concentration
DE60027581D1 (de) Design von immunogene
BR9908540A (pt) Molécula de ácido nucleico recombinante, célula hospedeira recombinante, composição farmacêutica, e, processo para induzir uma resposta imune contra vìrus de hepatite c em um humano não infectado por vìrus de hepatite c, para imunizar um humano suscetìvel a vìrus de hepatite c, e para tratar um humano que é infectado com vìrus de hepatite c
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DK1553979T3 (da) IHNV-G-fusionsprotein til immunistimulering
Belfaiza et al. E. coli aspartokinase II-homoserine dehydrogenase II polypeptide chain has a triglobular structure